A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer
Open Access
- 17 October 2008
- Vol. 113 (9), 2448-2456
- https://doi.org/10.1002/cncr.23863
Abstract
BACKGROUND. There have been few randomized studies of adjuvant chemotherapy using gemcitabine (GEM) in patients with resected pancreatic cancer. METHODS. Patients with invasive ductal pancreatic cancer who underwent radical surgery were enrolled and assigned to receive uracil/tegafur (UFT) and GEM together (GU) or GEM alone (G). GEM was administrated at a dosage of 1 g/m2 intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously. Eligibility included resection status 0 or 1, and no previous chemo‐ or/and radiation therapy. The primary endpoint was disease‐free survival (DFS), and secondary endpoints included overall survival (OS) and toxicity. RESULTS. Between 2002 and 2005, 100 patients were randomized into the 2 arms of the trial (50 patients to GU and 50 to G). One patient in the G group was found to be ineligible. Baseline characteristics were well balanced between the 2 groups. With a median observation period of 21 months, the 1‐ and 3‐year DFS rates were 50.0% and 17.7% in the GU group and 49.0% and 21.6% in the G group, respectively. The median OS was 21.2 months in the GU group and 29.8 months in the G group. Toxicity was minor and acceptable, less than grade 4 in both groups. CONCLUSIONS. Postoperative GEM‐based adjuvant chemotherapy was safe and well tolerated. However, addition of UFT with GEM did not improve DFS as compared with GEM alone. Further clinical trial resources for adjuvant chemotherapy should address other combinations and novel agents. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Cisplatin and 5-Fluorouracil Therapy after Curative Resection in Cases of Pancreatic CancerJapanese Journal of Clinical Oncology, 2006
- A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinomaSurgery, 2005
- A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancerSurgery, 2004
- Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancerInternational Journal of Clinical Oncology, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic CancerOncology, 2004
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater—results of a controlled, prospective, randomised multicentre studyEuropean Journal Of Cancer, 1993